Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
BACKGROUNDAn increase in intrahepatic triglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear.METHODSHepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both liver and whole-body insulin sensitivity were determined in individuals who were lean (n = 14), obese with normal IHTG content (n = 26), or obese with NAFLD (n = 27). Hepatic DNL was assessed using the deuterated water method corrected for the potential confounding contribution of adipose tissue DNL. Liver and whole-body insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose tracer infusion. Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%.RESULTSThe contribution of hepatic DNL to IHTG-palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively. Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations. Weight loss decreased IHTG content, in conjunction with a decrease in hepatic DNL and 24-hour plasma glucose and insulin concentrations.CONCLUSIONSThese data suggest hepatic DNL is an important regulator of IHTG content and that increases in circulating glucose and insulin stimulate hepatic DNL in individuals with NAFLD. Weight loss decreased IHTG content, at least in part, by decreasing hepatic DNL.TRIAL REGISTRATIONClinicalTrials.gov NCT02706262.FUNDINGThis study was supported by NIH grants DK56341 (Nutrition Obesity Research Center), DK20579 (Diabetes Research Center), DK52574 (Digestive Disease Research Center), and RR024992 (Clinical and Translational Science Award), and by grants from the Academy of Nutrition and Dietetics Foundation, the College of Natural Resources of UCB, and the Pershing Square Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, DNL has been associated with hepatic and whole-body IR (glucose metabolism),24,25 suggesting that IR may accelerate hepatic DNL.25”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [25]
In the citing paper
“In a well-designed study by Smith et al. [50], the contribution of hepatic DNL to intrahepatic TG palmitate was 11%, 19%, and 38% in the lean, obese, and obese-MASLD groups, respectively.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
In the citing paper
“Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“First, the long (3-5 week) duration of D2O tracer administration in our study accounted for labelling of the liver TG pools that turn over slowly (12) and provided an integrated assessment of DNL during daily fasting and fed conditions over several weeks.”
BackgroundMethodResultInfluentialA new predictive equation for resting energy expenditure in healthy individuals
Mifflin, M., St Jeor, S., Hill, L., Scott, B., Daugherty, S., & Koh, Y. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.2.241 · Cited by 2,544 · cited 2×
“The initial daily energy content of the diet provided 75% of estimated energy requirements (54); subsequent meals and energy”
BackgroundMethodObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Self-citationNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 1×
“Although the mechanism(s) responsible for the increase in hepatic DNL in people with NAFLD is not known, it is possible that increases in circulating insulin and glucose associated with hepatic and whole-body insulin resistance are involved in stimulating hepatic DNL because insulin and glucose activate SREBP-1c and C…”
Background
Research works printed but not linked: 2
- 10.1172/JCI22422 · DOI · Paper page
- 10.1016/S1097-2765(05)00010-9 · doi:10.1016/s1097-2765(05)00010-9 · Paper page
Cited by
Adipose tissue and insulin resistance in obese
Ahmed, B., Sultana, R., & Greene, M. W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111315 · Cited by 1,047
Why does obesity cause diabetes?
Klein, S., Gastaldelli, A., Yki-Järvinen, H., & Scherer, P. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.012 · Cited by 939
“Even people with a genetic variant of the patatin-like phospholipase domain-containing 3 gene, which markedly increases the risk of NAFLD, are unlikely to develop hepatic steatosis in the absence of obesity and concomitant insulin resistance (Stender et al., 2017).”
BackgroundSelf-citationTrends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
“Lipotoxic injury appears to occur in response to excessive levels of serum free fatty acids (FFAs) in hepatocytes.314 Circulating FFAs are the primary causes of liver fat accumulation in MAFLD that mainly occur due to lipolysis of adipose tissues, and partially from excess lipoprotein.315 Patients with MAFLD have incr…”
BackgroundDuell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727
Metabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
“In MAFLD, however, the rate of hepatic DNL is strongly increased and more than 25% of VLDL triglycerides can stem from DNL [92,94,95].”
BackgroundTanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
“Even if they are still insufficiently known data, IR seems to be one of the key events that appear in both disorders [32, 33].”
BackgroundLipid droplet biogenesis and functions in health and disease
Zadoorian, A., Du, X., & Yang, H. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00845-0 · Cited by 617
“Originating as simple steatosis, NAFLD can progress to steatohepatitis with fibrosis, cirrhosis, liver failure and potentially hepatocellular carcinoma 171 .”
InfluentialDysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 554
“Importantly, the molar ratio of VLDL-TG (particle TG content) to VLDL-ApoB100 (the number of particles) is elevated in nondiabetic obese individuals with high intrahepatic TG (measured by MRS), suggesting that the secreted VLDL particles are larger and resemble the pro-atherogenic VLDL1 [65].”
BackgroundInfluentialLipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics
Morigny, P., Boucher, J., Arner, P., & Langin, D. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00471-8 · Cited by 527
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Tilg, H., Adolph, T. E., Dudek, M., & Knolle, P. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00501-9 · Cited by 507
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 504
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451
Role of Insulin Resistance in MAFLD
Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084156 · Cited by 448
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Yoshino, M., Yoshino, J., Kayser, B. D., Patti, G. J., Franczyk, M. P., Mills, K. F., Sindelar, M., Pietka, T., Patterson, B. W., Imai, S.-I., et al. (2021) · Science · doi:10.1126/science.abe9985 · Cited by 439
Self-citationExercise and metabolic health: beyond skeletal muscle
Thyfault, J. P., & Bergouignan, A. (2020) · Diabetologia · doi:10.1007/s00125-020-05177-6 · Cited by 410
“For reasons not understood, the liver becomes selectively insulin resistant in controlling glucose output but remains highly sensitive to the lipogenic effects of insulin [6].”
BackgroundStefan, N., Yki-Järvinen, H., & Neuschwander-Tetri, B. A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 392
Lipogenesis inhibitors: therapeutic opportunities and challenges
Batchuluun, B., Pinkosky, S. L., & Steinberg, G. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00367-2 · Cited by 399
NAFLD: Mechanisms, Treatments, and Biomarkers
Nassir, F. (2022) · Biomolecules · doi:10.3390/biom12060824 · Cited by 405
“Insulin resistance drives de novo lipogenesis (DNL) in NAFLD [38,39].”
BackgroundBadmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E. (2022) · Clinical Science · doi:10.1042/cs20220572 · Cited by 370
“In addition, increased circulating insulin levels stimulate hepatic de novo lipogenesis in patients with MAFLD [12].”
BackgroundMetabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
“Prolonged ingestion of (2)H2O over 3e5 weeks, with correction for adipose tissue FA synthesis, revealed an even higher contribution of 38% of hepatic DNL to hepatic TAG among obese glucose-intolerant individuals with NAFLD, compared with the 19% and 11% in glucose-tolerant obese and lean individuals without NAFLD, com…”
ResultA guide to understanding endoplasmic reticulum stress in metabolic disorders
Lemmer, I. L., Willemsen, N., Hilal, N., & Bartelt, A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101169 · Cited by 310
“Somewhat paradoxically, lipogenesis in the liver is linked to a phenomenon referred to as selective insulin resistance, as particularly SREBP and MLX interacting protein-like (MLXIPL, also known as ChREBP)-mediated lipogenesis pathways are upregulated in obesity, while other insulin-responsive mechanisms are not [171].”
BackgroundDiabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans-Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Susztak, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 292
Dietary carbohydrates and fats in nonalcoholic fatty liver disease
Yki-Järvinen, H., Luukkonen, P. K., Hodson, L., & Moore, J. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00472-y · Cited by 294
Molecular aspects of fructose metabolism and metabolic disease
Herman, M. A., & Birnbaum, M. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.010 · Cited by 290
The role of hepatokines in NAFLD
Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H.-U., & White, M. F. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.006 · Cited by 282
Bo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
Physiological and pathological roles of lipogenesis
Jeon, Y. G., Kim, Y. Y., Lee, G., & Kim, J. B. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00786-y · Cited by 243
Effects of diet versus gastric bypass on metabolic function in diabetes
Yoshino, M., Kayser, B. D., Yoshino, J., Stein, R. I., Reeds, D., Eagon, J. C., Eckhouse, S. R., Watrous, J. D., Jain, M., Knight, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003697 · Cited by 246
Self-citationUnderstanding the extracellular vesicle surface for clinical molecular biology
Hallal, S., Tűzesi, Á., Grau, G. E., Buckland, M. E., & Alexander, K. L. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12260 · Cited by 236
“, 2010), non-fatty liver disease, obesity and virus-infected cells (Ameer et al., 2014; Smith et al., 2020), and”
BackgroundHepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD
Mashek, D. G. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101115 · Cited by 232
“The contribution of FAs from DNL is markedly increased in subjects with NAFLD and can account for 30e 40% of hepatic FAs [9,10].”
BackgroundTherapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus
Yong, J., Johnson, J. D., Arvan, P., Han, J., & Kaufman, R. J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00510-4 · Cited by 228
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Lee, E., Korf, H., & Vidal-Puig, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.024 · Cited by 222
Metabolic drivers of non-alcoholic fatty liver disease
Bence, K. K., & Birnbaum, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101143 · Cited by 221
Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms
Steinberg, G. R., Valvano, C. M., De Nardo, W., & Watt, M. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.033 · Cited by 240
Loomba, R., Mohseni, R., Lucas, K. J., Gutierrez, J. A., Perry, R. G., Trotter, J. F., Rahimi, R. S., Harrison, S. A., Ajmera, V., Wayne, J. D., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.025 · Cited by 220
Xue, Y., Xu, J., Li, M., & Gao, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.951689 · Cited by 210
“; the activated hepatic gluconeogenesis also increases glucose level (4, 34, 35).”
BackgroundInfluentialBrain insulin signalling in metabolic homeostasis and disease
Scherer, T., Sakamoto, K., & Buettner, C. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00498-x · Cited by 205
Advances in Understanding of the Role of Lipid Metabolism in Aging
Chung, K. W. (2021) · Cells · doi:10.3390/cells10040880 · Cited by 182
“Experimental animal models have revealed the importance of de novo lipogenesis factors in the development of hepatosteatosis and insulin resistance [47,51].”
BackgroundTherapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F., & Mehal, W. Z. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 169
“…of lipids is a major contributor to hepatocyte stress and damage in MASLD, mainly due to DNL. Rates of DNL are clearly elevated in MASLD 30,153 , and therefore several small-molecule inhibitors of this pathway have been developed, some of which have reached phase II clinical trials 47 .”
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Luukkonen, P. K., Qadri, S., Ahlholm, N., Porthan, K., Männistö, V., Sammalkorpi, H., Penttilä, A. K., Hakkarainen, A., Lehtimäki, T. E., Gaggini, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.013 · Cited by 170
Singh, A., Shadangi, S., Gupta, P. K., & Rana, S. (2025) · Comprehensive Physiology · doi:10.1002/cph4.70003 · Cited by 163
“…the buildup of ectopic IMCL and the suppression of muscle insulin signaling by DAG/PKCθ redirects consumed glucose to the liver, where the simultaneous presence of postprandial hyperinsulin-emia and hyperglycemia elevates de novo lipogenesis in the liver (Smith et al. 2020; Li, Chi, et al. 2022).”
SREBP-1c and lipogenesis in the liver: an update
Ferré, P., Phan, F., & Foufelle, F. (2021) · Biochemical Journal · doi:10.1042/bcj20210071 · Cited by 162
The small intestine shields the liver from fructose-induced steatosis
Jang, C., Wada, S., Yang, S., Gosis, B., Zeng, X., Zhang, Z., Shen, Y., Lee, G., Arany, Z., & Rabinowitz, J. D. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0222-9 · Cited by 160
Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity
Petersen, M. C., Smith, G. I., Palacios, H. H., Farabi, S. S., Yoshino, M., Yoshino, J., Cho, K., Davila-Roman, V. G., Shankaran, M., Barve, R. A., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.002 · Cited by 149
Self-citationKloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 197
Glucocorticoid-Induced Fatty Liver Disease
Rahimi, L., Rajpal, A., & Ismail-Beigi, F. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s247379 · Cited by 144
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
“Interestingly, DNL has been associated with hepatic and whole-body IR (glucose metabolism), 24,25 suggesting that IR may accelerate hepatic DNL. 25 Smith et al. hypothesised that there is a selective/partial IR pathway, i.e . it exists at the level of glucose metabolism but not of hepatic…”
Decreased Adipose Tissue Oxygenation Associates with Insulin Resistance in Individuals with Obesity
Cifarelli, V., Beeman, S. C., Smith, G. I., Yoshino, J., Morozov, D., Beals, J. W., Kayser, B. D., Watrous, J. D., Jain, M., Patterson, B. W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141828 · Cited by 132
Self-citationEvolving Role for Pharmacotherapy in NAFLD/NASH
Attia, S. L., Softic, S., & Mouzaki, M. (2021) · Clinical and Translational Science · doi:10.1111/cts.12839 · Cited by 129
“This review summarizes emerging pharmacotherapies for the treatment of adult and pediatric NAFLD.”
BackgroundInfluentialNon‐alcoholic fatty liver disease and type 2 diabetes: An update
Lee, C., Lui, D. T. W., & Lam, K. S. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13756 · Cited by 159
MASH: the nexus of metabolism, inflammation, and fibrosis
Steinberg, G. R., Carpentier, A. C., & Wang, D. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186420 · Cited by 156
“Highlighting the important contribution and overlap between adipose tissue insulin resistance and DNL are recent findings showing that in people with MASLD, DNL accounts for approximately 40% of total tri-glyceride accretion during the postprandial period (119).”
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
Esler, W. P., & Cohen, D. E. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.042 · Cited by 111
The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease
Grefhorst, A., van de Peppel, I. P., Larsen, L. E., Jonker, J. W., & Holleboom, A. G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601627 · Cited by 131
“Dietary carbohydrates are the most important source of TGs derived by DNL and this process is stimulated by insulin.”
BackgroundInfluentialHepatic sexual dimorphism — implications for non-alcoholic fatty liver disease
Lefèbvre, P., & Staels, B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00538-6 · Cited by 143
Roles of Ceramides in Non-Alcoholic Fatty Liver Disease
Hajduch, É., Lachkar, F., Ferré, P., & Foufelle, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040792 · Cited by 126
“Several studies using stable isotopes have shown that lipogenesis is increased 3 to 5 fold in human NAFLD subjects and can account for up to 25–40% of TG fatty acids [75,76,79,84].”
BackgroundFrom NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
Boccatonda, A., Andreetto, L., D’Ardes, D., Cocco, G., Rossi, I., Vicari, S., Schiavone, C., Cipollone, F., & Guagnano, M. T. (2023) · Biomedicines · doi:10.3390/biomedicines11030883 · Cited by 129
“Furthermore, insulin resistance increases de novo lipogenesis (DNL) in NAFLD [45].”
BackgroundZhao, Z., Wang, Z., Zhou, D., Han, Y., Ma, F., Hu, Z., Xin, F., Liu, X., Ren, T., Zhang, F., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.05.006 · Cited by 126
“(Cell Mol Gastroenterol Hepatol 2021;12:857–871; https://doi.org/ 10.1016/j.jcmgh.2021.05.006) Keywords: Sodium Butyrate; Insulin-Induced Gene; LKB1; Hepatic Lipogenesis; NAFLD. epatic steatosis is a major characteristic of nonal- *Authors share co-first authorship Abbreviations used in this paper: ACC, acetyl-CoA car…”
BackgroundInfluentialMitochondrial oxidative function in NAFLD: Friend or foe?
Shum, M., Ngo, J., Shirihai, O. S., & Liesa, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101134 · Cited by 106
“In contrast to HFD-induced hepatic steatosis in mice, up to 38% of hepatic TG accumulated in humans with fatty liver stems from de novo synthesized fatty acids [57].”
BackgroundInsights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Arrese, M., Arab, J. P., Barrera, F., Kaufmann, B., Valenti, L., & Feldstein, A. E. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730927 · Cited by 103
The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD
Hong, T., Chen, Y., Li, X., & Lü, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6889533 · Cited by 123
“The human isotopelabeling studies showed that DNL is significantly elevated in patients with NAFLD, and the portion DNL accounts for intrahepatic triglyceride-palmitate increases as the severity of insulin resistance increases, about 11% in the lean group, 19% in the obese group, and 38% in the obeseNAFLD group [47, 4…”
BackgroundLuukkonen, P. K., Porthan, K., Ahlholm, N., Rosqvist, F., Dufour, S., Zhang, X.-M., Lehtimäki, T. E., Seppänen, W., Orho-Melander, M., Hodson, L., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.008 · Cited by 97
The pathophysiology of MASLD: an immunometabolic perspective
Schwärzler, J., Grabherr, F., Grander, C., Adolph, T. E., & Tilg, H. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2294046 · Cited by 117
“…alterations regarding lipid metabolism are involved in the pathogenesis of MASLD: an increased supply of FFAs, either derived from the diet or VAT depots, to the liver-induced DNL [49,50], while an impairment of fatty acid oxidation and export of lipids from the liver was observed [51,52].”
Thibaut, R., Gage, M. C., Pineda‐Torra, I., Chabrier, G., Venteclef, N., & Alzaid, F. (2022) · The FEBS Journal · doi:10.1111/febs.15877 · Cited by 95
Tracing insights into de novo lipogenesis in liver and adipose tissues
Wallace, M., & Metallo, C. M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.02.012 · Cited by 107
Hydes, T., Alam, U., & Cuthbertson, D. J. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.640557 · Cited by 117
“Keywords: non-alcoholic fatty liver disease, carbohydrate, saturated fat, over-feeding, de novo lipogenesis (DNL), adipose tissue expandability, fructose, randomized study Hydes et al. NAFLD: Fat, Carbohydrate or Calories”
BackgroundInfluentialGrowth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease
Dichtel, L. E., Córdoba‐Chacón, J., & Kineman, R. D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac088 · Cited by 99
NAFLD and thyroid function: pathophysiological and therapeutic considerations
Hatziagelaki, E., Paschou, S. A., Schön, M., Psaltopoulou, T., & Roden, M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.08.001 · Cited by 93
“Insulin-sensitizing drugs, such as metformin and pioglitazone, constitute treatment targets as insulin resistance is actively involved in hepatic fat accumulation [72].”
BackgroundA review of non‐alcoholic fatty liver disease in non‐obese and lean individuals
Ahadi, M., Molooghi, K., Masoudifar, N., Namdar, A. B., Vossoughinia, H., & Farzanehfar, M. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15353 · Cited by 107
Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis
Lambie, M., Bonomini, M., Davies, S., Accili, D., Arduini, A., & Zammit, V. A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.06.001 · Cited by 90
“With systemic hyperinsulinemia, de novo lipogenesis and triglyceride synthesis and secretion are activated [10].”
BackgroundTarantino, G., Balsano, C., Santini, S. J., Brienza, G., Clemente, I., Cosimini, B., & Sinatti, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413424 · Cited by 94
Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease
ter Horst, K. W., Vatner, D. F., Zhang, D., Cline, G. W., Ackermans, M. T., Nederveen, A. J., Verheij, J., Demirkiran, A., van Wagensveld, B. A., Dallinga-Thie, G. M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1644 · Cited by 88
Cohen, C. C., Li, K. W., Alazraki, A. L., Beysen, C., Carrier, C., Cleeton, R. L., Dandan, M., Figueroa, J., Knight‐Scott, J., Knott, C. J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150996 · Cited by 92
“In these studies, hepatic DNL was correlated with hepatic fat (11, 12) as well as 24-hour plasma glucose and insulin and systemic and hepatic insulin resistance (measured by 2-stage glucose clamp technique) (12), and fell with weight loss (12).”
BackgroundMethodResultInfluentialSelf-citationGnoni, A., Stanca, B. D. C., Giannotti, L., Gnoni, G. V., Siculella, L., & Damiano, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031044 · Cited by 91
“In IR conditions, hepatic DNL is stimulated through the activation of sterol regulatory element-binding protein-1 (SREBP-1), the main transcription factor implied in lipogenic gene upregulation in steatotic hepatocytes [4,5].”
BackgroundRao, G., Peng, X., Li, X., An, K., He, H., Fu, X., Li, S., & An, Z. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1294267 · Cited by 111
“…is still unknown, but under the background of systemic insulin resistance, due to the increase of circulating insulin and glucose, the activation of two main transcription factors, SREBP-1c and carbohydrate-responsive element binding protein (ChREBP), has been considered a core driving factor (43).”
BackgroundRamírez‐Manent, J. I., Jover, A. M., Martinez, C. S., Tomás-Gil, P., Martí-Lliteras, P., & López‐González, Á. A. (2023) · Nutrients · doi:10.3390/nu15020257 · Cited by 111
“Both processes favour abdominal obesity [22], the formation of triglycerides in the liver [23] and the release of very-low-density lipoproteins (VLDLs), the latter situations of which cause dyslipidaemia [24].”
BackgroundTruong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“Furthermore, non-obese participants who achieved a 10% weight loss showed a 35% decrease DNL in li-poprotein-TG and a 50% reduction in intrahepatic TG [50].”
InfluentialThe Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights
Federico, A., Rosato, V., Masarone, M., Torre, P., Dallio, M., Romeo, M., & Persico, M. (2021) · Nutrients · doi:10.3390/nu13041314 · Cited by 91
Chop / Ddit3 depletion in β cells alleviates ER stress and corrects hepatic steatosis in mice
Yong, J., Parekh, V. S., Reilly, S. M., Nayak, J., Chen, Z., Lebeaupin, C., Jang, I., Zhang, J., Prakash, T. P., Sun, H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aba9796 · Cited by 81
“Consistent with a recent report that demonstrated IR as a causal factor for hepatic de novo lipogenesis in human NAFLD (7), it will be of interest to investigate whether the reduced fatty liver that we observed here reflects reduced de novo hepatic lipogenesis or increased export from hepatocytes or fatty acid oxidati…”
BackgroundInfluentialUnderstanding the cause of type 2 diabetes
Taylor, R. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00157-8 · Cited by 95
Cusi, K., Alkhouri, N., Harrison, S. A., Fouqueray, P., Moller, D. E., Hallakou-Bozec, S., Bolze, S., Grouin, J.-M., Jeannin Megnien, S., Dubourg, J., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00300-9 · Cited by 75
Smith, G. I., Polidori, D. C., Yoshino, M., Kearney, M. L., Patterson, B. W., Mittendorfer, B., & Klein, S. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136756 · Cited by 78
“Although hyperinsulinemia and insulin resistance are likely involved in the pathogenesis of NAFLD (5), excess intrahepatic triglyceride (IHTG) content could also contribute to hyperinsulinemia and insulin resistance.”
BackgroundSelf-citationDysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
Bhat, N., & Mani, A. (2023) · Nutrients · doi:10.3390/nu15102323 · Cited by 92
“While this may explain the 60% contribution to hepatic fat in NAFLD patients, the increase of fatty acid synthesis by the DNL pathway still remains unexplained [11,112].”
BackgroundHarrison, S. A., Manghi, F. P., Smith, W. B., Alpenidze, D., Aizenberg, D., Klarenbeek, N., Chen, C.-Y., Zuckerman, E., Ravussin, E., Charatcharoenwitthaya, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01861-9 · Cited by 75
Self-citationOrosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis
Zhou, B., Luo, Y., Ji, N., Hu, C., & Lu, Y. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00627-4 · Cited by 75
Excessive Gluconeogenesis Causes the Hepatic Insulin Resistance Paradox and Its Sequelae
Onyango, A. N. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12294 · Cited by 93
Hepatic glycogenesis antagonizes lipogenesis by blocking S1P via UDPG
Chen, J., Zhou, Y., Liu, Z., Lu, Y. H., Jiang, Y., Cao, K., Zhou, N., Wang, D., Zhang, C., Zhou, N., et al. (2024) · Science · doi:10.1126/science.adi3332 · Cited by 84
Fructose drives de novo lipogenesis affecting metabolic health
Geidl, B., & Gerber, P. A. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0270 · Cited by 100
Modification of lipoprotein metabolism and function driving atherogenesis in diabetes
Luciani, L., Pedrelli, M., & Parini, P. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117545 · Cited by 72
Taylor, R., Barnes, A. C., Hollingsworth, K. G., Irvine, K. M., Solovyova, A. S., Clark, L., Kelly, T., Martin-Ruiz, C., Romeres, D., Koulman, A., et al. (2023) · Clinical Science · doi:10.1042/cs20230586 · Cited by 71
“The > 50% decrease in plasma triglycerides containing predominantly palmitic acid reflects decreased fasting de novo lipogenesis [13], as previously documented with weight loss in heavier people [4,5,21,28].”
Hernandez, P., Passi, N., Modarressi, T., Kulkarni, V., Soni, M., Burke, F., Bajaj, A., & Soffer, D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00962-z · Cited by 71
An, H., Jang, Y., Choi, J.-I., Hur, J., Kim, S., & Kwon, Y. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.188 · Cited by 80
Lipodystrophy: A paradigm for understanding the consequences of "overloading" adipose tissue
Lim, K., Haider, A., Adams, C., Sleigh, A., & Savage, D. B. (2020) · Physiological Reviews · doi:10.1152/physrev.00032.2020 · Cited by 110
Li, N., Yin, L., Shang, J., Liang, M., Liu, Z., Yang, H., Qiang, G., Du, G., & Yang, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115113 · Cited by 78
Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent
Semova, I., & Biddinger, S. B. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.12.001 · Cited by 75
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Martínez‐Arranz, I., Bruzzone, C., Noureddin, M., Gil‐Redondo, R., Mincholé, I., Bizkarguenaga, M., Arretxe, E., Iruarrizaga‐Lejarreta, M., Fernández‐Ramos, D., Lopitz‐Otsoa, F., et al. (2022) · Hepatology · doi:10.1002/hep.32427 · Cited by 65
Self-citationDysregulation of hepatic metabolism with obesity: factors influencing glucose and lipid metabolism
Nagarajan, S. R., Cross, E., Sanna, F., & Hodson, L. (2021) · Proceedings of The Nutrition Society · doi:10.1017/s0029665121003761 · Cited by 71
“In contrast, Smith et al.(45) reported that hepatic DNL was significantly higher in obese non-NAFLD compared to lean subjects despite no significant difference in fasting plasma insulin concentrations.”
InfluentialHepatology and Nutrition (ESPGHAN) European Society for Pediatric Gastroenterology, North American Society for Pediatric Gastroenterology, H., Latin‐American Society for Pediatric Gastroenterology, H., Hepatology and Nutrition (APPSPGHAN) Asian Pan‐Pacific Society for Pediatric Gastroenterology, Pan Arab Society for Pediatric Gastroenterology and Nutrition (PASPGHAN), & Gastroenterology and Nutrition (FISPGHAN) Federation of International Societies of Pediatric Hepatology (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12156 · Cited by 72
Leptin Increases Hepatic Triglyceride Export via a Vagal Mechanism in Humans
Metz, M., Beghini, M., Wolf, P. S., Pfleger, L., Hackl, M. T., Bastian, M., Freudenthaler, A., Harreiter, J., Zeyda, M., Baumgartner-Parzer, S. M., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.020 · Cited by 69
Metadata
- Authors
- Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., Sirlin, C. B., Talukdar, S., Hellerstein, M. K., & Klein, S.
- Affiliations
- Washington University in St. Louis (US)
- University of California, Berkeley (US)
- University of California San Diego (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Klein, Samuel
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-04
- Volume
- 130
- Issue
- 3
- Pages
- 1453-1460
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7269561
- OpenAlex
- W2993862932
- Cited by
- 771
- References
- 65
- Citations by year
- 2026: 121 · 2025: 136 · 2024: 153 · 2023: 123 · 2022: 104 · 2021: 92 · 2020: 40
- FWCI
- 44.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (DK56341,DK20579,DK52574,RR024992)
- College of Natural Resources, University of California at Berkeley (N/A)
- Pershing Square Foundation (N/A)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, hepatic de novo lipogenesis, insulin resistance, intrahepatic triglyceride, hepatic insulin sensitivity, weight loss, obesity, hepatic steatosis, plasma glucose, hyperinsulinemic-euglycemic clamp
- MeSH terms
- Adult, Blood Glucose, Female, Humans, Insulin, Insulin Resistance, Liver, Male, Triglycerides, Palmitic Acid, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.